Sunbelt Securities Inc. trimmed its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 51.2% during the 1st quarter, HoldingsChannel reports. The fund owned 5,357 shares of the company’s stock after selling 5,631 shares during the quarter. Sunbelt Securities Inc.’s holdings in Astrazeneca were worth $1,056,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently modified their holdings of the company. Pursuit Wealth Management LLC purchased a new position in Astrazeneca in the fourth quarter valued at approximately $636,000. Penobscot Investment Management Company Inc. lifted its position in shares of Astrazeneca by 17.2% during the 4th quarter. Penobscot Investment Management Company Inc. now owns 83,539 shares of the company’s stock worth $7,680,000 after buying an additional 12,255 shares during the last quarter. Aaron Wealth Advisors LLC lifted its position in shares of Astrazeneca by 31.9% during the 4th quarter. Aaron Wealth Advisors LLC now owns 27,984 shares of the company’s stock worth $2,573,000 after buying an additional 6,769 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Astrazeneca by 8.1% in the 4th quarter. Assetmark Inc. now owns 335,387 shares of the company’s stock valued at $30,832,000 after buying an additional 25,004 shares in the last quarter. Finally, Cambiar Investors LLC boosted its holdings in shares of Astrazeneca by 2.0% in the 4th quarter. Cambiar Investors LLC now owns 276,150 shares of the company’s stock valued at $25,386,000 after buying an additional 5,326 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages recently commented on AZN. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Weiss Ratings downgraded shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Finally, Bank of America restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Astrazeneca presently has an average rating of “Moderate Buy” and a consensus price target of $211.00.
Astrazeneca Price Performance
Astrazeneca stock opened at $171.50 on Friday. Astrazeneca Plc has a 12 month low of $145.79 and a 12 month high of $212.71. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.71. The business has a 50 day simple moving average of $179.37 and a 200-day simple moving average of $187.83. The stock has a market capitalization of $265.97 billion, a PE ratio of 25.63, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24.
Astrazeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.13. The company had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. Astrazeneca’s revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.17 EPS. Equities analysts predict that Astrazeneca Plc will post 10.22 earnings per share for the current year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Read More
- Five stocks we like better than Astrazeneca
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
